233754-93-3

Upstream product

• 233754-60-4 methyl 2-{[2-(4-biphenylcarbonyl)aminobenzyl]-(4-methoxybenzenesulfonyl)amino}acrylate 
• 233754-50-2 methyl 2-[(2-Aminobenzyl)-(4-methoxybenzenesulfonyl)amino]-3-hydroxypropionate 
• 233754-49-9 methyl 3-Hydroxy-2-[(4-methoxybenzenesulfonyl)-(2-nitrobenzyl)-amino]propionate 
• 85622-74-8 methyl 3-hydroxy-2-(4-methoxybenzenesulfonylamino)propionate 
• 98-68-0 4-methoxy-phenyl-sulphonyl chloride 
• 233754-73-9 methyl 1-(4-biphenylcarbonyl)-4-(4-methoxybenzenesulfonyl)-2,3,4,5-tetrahydro-1H-[1,4]benzodiazepine-3-carboxylate 

Relevant academic research and scientific papers

2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids

Compounds having the following formula: ? are useful in treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss.

Benzodiazepine inhibitors of the MMPs and TACE

A series of benzodiazepine inhibitors of the MMPs and TACE has been developed. These compounds display an interesting selectivity profile and should be useful tools for exploring the biological relevance of such selectivity.

2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids

Compounds are provided having the following formula: wherein R, R1, R2, R3, and R4 are defined in the specification, which have matrix metalloproteinase inhibiting activity.